论文部分内容阅读
目的研究Ⅱ期结肠癌患者术后行辅助化疗前后血清Smad4表达水平及临床意义。方法 110例Ⅱ期结肠癌术后辅助化疗的患者,根据有无复发情况分为复发组(37例)和未复发组(73例);应用酶联免疫吸附剂测定法(ELISA)对其辅助化疗前后血清Smad4水平进行检测。分析血清Smad4水平与患者无病生存时间的关系。结果未复发组化疗后血清Smad4水平与化疗前相比明显升高,差异有统计学意义(P<0.05);复发组化疗前血清Smad4显著低于未复发组,两组比较差异有统计学意义(P<0.05)。患者血清Smad4水平与患者无病生存期呈正相关(I=-2.03,P<0.05)。结论血清Smad4水平变化可作为评测Ⅱ期结肠癌患者术后辅助化疗疗效及预后的重要分子生物学指标。
Objective To study the serum level of Smad4 in patients with stage Ⅱ colon cancer before and after adjuvant chemotherapy and its clinical significance. Methods One hundred and ten patients with postoperative adjuvant chemotherapy for stage Ⅱ colon cancer were divided into the recurrent group (n = 37) and the non-recurrent group (n = 73) according to the presence or absence of recurrence. Enzyme-linked immunosorbent assay (ELISA) Serum Smad4 levels were measured before and after chemotherapy. The relationship between serum Smad4 level and disease-free survival time was analyzed. Results The level of Smad4 in non-recurrent group was significantly higher than that before chemotherapy (P <0.05), and the level of Smad4 in recurrent group was significantly lower than that in non-recurrent group (P <0.05). Serum Smad4 levels in patients with disease-free survival was positively correlated (I = -2.03, P <0.05). Conclusions The change of serum Smad4 level may be used as an important molecular biological index to evaluate the efficacy and prognosis of postoperative adjuvant chemotherapy in patients with stage Ⅱ colon cancer.